{
    "clinical_study": {
        "@rank": "110876", 
        "arm_group": [
            {
                "arm_group_label": "PF-06305591 Dose 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "PF-06305591 Dose 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the pharmacological activity of PF-06305591 in healthy male\n      volunteers by assessing the effects of two dose levels of PF-06305591 on cold pain intensity\n      evoked by keeping non-dominant hand into a water bath kept at 2+/- degrees."
        }, 
        "brief_title": "Cold Pressor Test is Used in This Study to Assess the Effect of PF-06305591 on Pain Intensity Evoked by Cold in Healthy Male Subjects", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is\n             defined as no clinically relevant abnormalities identified by a detailed medical\n             history, full physical examination, including blood pressure and pulse rate\n             measurement, 12-lead ECG and clinical laboratory tests.\n\n          -  Body Mass Index (BMI) of 17.5 to 35 kg/m2; and a total body weight >50 kg (110 lbs).\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease (including drug allergies, but excluding untreated, asymptomatic,\n             seasonal allergies at the time of dosing).\n\n          -  Any condition possibly affecting drug absorption (eg, gastrectomy).\n\n          -  Subjects unable to tolerate pre-study Cpressor testing at screening.\n\n          -  Subjects with an average pain (AUC 0 to 120 sec) in the pre-study Cpressor test of\n             less than or equal to 20.\n\n          -  Broken skin on hands or forearms"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812265", 
            "org_study_id": "B5281003"
        }, 
        "intervention": [
            {
                "arm_group_label": "PF-06305591 Dose 1", 
                "description": "single Dose", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "PF-06305591 Dose 2", 
                "description": "single Dose", 
                "intervention_name": "PF-06305591", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Single Dose", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5281003&StudyName=Cold%20Pressor%20test%20is%20used%20in%20this%20study%20to%20assess%20the%20effect%20of%20PF-06305591%20on%20pain%20intensity%20evoked%20by%20cold%20in%20Healthy%20Male%20Sub"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Bruxelles", 
                    "country": "Belgium", 
                    "zip": "B-1070"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Crossover Study To Investigate The Effects Of Pf-06305591 On Cold Pain In Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Commission d'Ethique Biom\u00e9dicale Hospitalo-Facultaire"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change from Baseline in 10 cm VAS pain score; 10-point pain intensity ordinal rating system: 0 = no pain, 1-3 = mild pain, 4-6 = moderate pain, 7-9 = severe pain, 10 = worst possible pain. Change = scores at observation minus score at Baseline in a 2 minute assessment.", 
            "measure": "Change From Baseline in Visual Analogue Scale (VAS) Score at time X, measured within a 2 minute interval", 
            "safety_issue": "No", 
            "time_frame": "24h"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }, 
            {
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "24h"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}